<SEC-DOCUMENT>0001193125-24-274918.txt : 20241211
<SEC-HEADER>0001193125-24-274918.hdr.sgml : 20241211
<ACCEPTANCE-DATETIME>20241211090425
ACCESSION NUMBER:		0001193125-24-274918
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20241211
DATE AS OF CHANGE:		20241211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279773
		FILM NUMBER:		241540339

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d904031d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-279773</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
December&nbsp;2, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>8,850,000 American Depositary Shares representing 885,000,000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g904031g1211015249894.jpg" ALT="LOGO" STYLE="width:2.25139in;height:0.646528in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December&nbsp;2, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-279773),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on December&nbsp;11, 2024 (the &#147;December 11, 2024 Form <FONT STYLE="white-space:nowrap">6-K&#148;).</FONT> Accordingly, we have
attached the December&nbsp;11, 2024 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates
and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be
read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On December&nbsp;10, 2024, the last reported sale
price of the ADSs on Nasdaq was $3.59 per ADS. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities
involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 9 of the Prospectus and the &#147;Risk Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus supplement is December&nbsp;11, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of December, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;11, 2024, Kazia Therapeutics Limited (the &#147;Company&#148;) issued a press release titled, &#147;Kazia
Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium&#148;. A copy of this release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained
herein, including Exhibit 99.1, except for the quote of Dr.&nbsp;John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company&#146;s registration statements on Form <FONT STYLE="white-space:nowrap">F-3</FONT>
(File <FONT STYLE="white-space:nowrap">No.&nbsp;333-276091</FONT> and <FONT STYLE="white-space:nowrap">333-281937).</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT
LIST </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Kazia Therapeutics Limited dated December&nbsp;11, 2024</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited </B>(Registrant)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: 11&nbsp;December 2024</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g904031g1211020047388.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11&nbsp;December 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative
Breast Cancer Model at the San Antonio Breast Cancer Symposium </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, December&nbsp;11, 2024 &#150; Kazia Therapeutics Limited (NASDAQ: KZIA), an
oncology-focused drug development, announced that data from two abstracts will be presented at the San Antonio Breast Cancer Symposium highlighting the activity the Company&#146;s lead product candidate, paxalisib, for the potential treatment of
immunotherapy-resistant triple negative breast cancer (TNBC) and HER2 positive metastatic breast cancer with active brain metastases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Immunotherapy-resistant triple negative breast cancer represents one of the most
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> areas of breast cancer, with a growing number of patients who have failed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> immunotherapy and require new treatment options,&#148; said John Friend, M.D., President and Chief Executive Officer of Kazia Therapeutics. &#147;These
new preclinical data highlight the potential therapeutic synergies between paxalisib and the checkpoint inhibitor, pembrolizumab (KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>), when used in combination in a preclinical model of
immunotherapy-resistant triple negative breast cancer. Furthermore, these data also show synergies when paxalisib is combined with the PARP inhibitor, olaparib (LYNPARZA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>), which is approved
for the treatment of advanced BRCA-mutated HER2 negative metastatic breast cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In a second abstract, clinical investigators presented efficacy
and safety data in heavily pretreated patients (median prior 8 lines of therapy) with HER2 positive breast cancer with active brain metastases. Although the primary endpoint of overall response rate (ORR) was not met, patients receiving a
combination of paxalisib and trastuzumab (ENHERTU<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>) had a median overall survival of 16.5 months, which compares favorably versus historical control studies.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presentation Details: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Abstract&nbsp;Number:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">SESS-2122</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Title&nbsp;(P3-06-27):</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Immunotherapy and PI3K/mTOR inhibition combination to mediate metastasis and immunotherapy resistance in triple-negative breast cancer</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Presenting&nbsp;Author:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">John Friend, M.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date/Time:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">December&nbsp;12, 2024, <FONT STYLE="white-space:nowrap">12:00-2:00</FONT> pm CT</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conclusions:</B> The addition of paxalisib to immunotherapy in the 4T1 TNBC mouse model reduced primary tumor burden, lung
metastases, and liver inflammation whilst overcoming toxicity complications and resistance associated with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> immunochemotherapy. Paxalisib in combination
with the PARP inhibitor olaparib, but not monotherapy alone, also reduced primary tumor burden and metastases. Moving forward, work is ongoing to elucidate the PI3K-mTOR mechanism of overcoming metastasis and drug resistance as well as the
translation of the data into a clinical development program for patients with TNBC and advanced breast cancer </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g904031g1211020047388.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Abstract&nbsp;Number:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SESS-1433</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Title&nbsp;(P5-05-04):</FONT></FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Final results of a phase II trial evaluating paxalisib with trastuzumab for patients (pts) with&nbsp;HER2 positive metastatic breast cancer&nbsp;with active brain metastases.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Presenting&nbsp;Authors:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jose Leone and <FONT STYLE="white-space:nowrap">Co-Author(s):</FONT> Jose Pablo Leone, Noah Graham, Nabihah Tayob, Heather A. Parsons, Jorge Gomez Tejeda Za&ntilde;udo, Raechel Davis, Molly K. DiLullo, Jennifer A. Ligibel, Filipa
Lynce, Jing Ni, Eric P. Winer, Jean Zhao, Rinath M. Jeselsohn, Nancy U. Lin</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date/Time:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">December&nbsp;13, 2024, <FONT STYLE="white-space:nowrap">12:30-2:00</FONT> pm CT</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conclusions:</B> In this&nbsp;heavily <FONT STYLE="white-space:nowrap">pre-treated&nbsp;population</FONT> of pts with HER2+
active BCBM, the combination of paxalisib 30 mg daily with trastuzumab was feasible, with a toxicity profile consistent with a class effect of PI3K/mTOR inhibitors. However, it was associated with minimal clinical activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations Contact </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alex Starr </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Managing Director, LifeSci Advisors</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">astarr@lifesciadvisors.com
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">201-786-8795</FONT></FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics
Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat
multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2 study in glioblastoma reported early signals of clinical activity in 2021, and a
pivotal study in glioblastoma, GBM AGILE, has been completed and a Type C meeting with the FDA is scheduled in December 2024. Other clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS
lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the FDA in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020.
Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan
Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was
licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and preliminary data was
presented at 15th Biennial Ovarian Cancer Research Symposium in September 2024. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g904031g1211020047388.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148;
&#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or
prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials,
Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory
agencies, and the potential market opportunity for paxalisib. Such statements are based on Kazia&#146;s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and
uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to
regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the United
States Securities and Exchange Commission, or the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise,
except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorized for release by Dr John Friend, CEO. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g904031g1211015249894.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g904031g1211015249894.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -4# 2(  A$! Q$!_\0
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M'^&0=/S'%;35T9Q=F>Z#I43JA)+JIP,Y([5(.E<9\1_$7]A>&Y$B?%W=YBB
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..B@8M%)10 M%)10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g904031g1211020047388.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g904031g1211020047388.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U *@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^F22QPQF
M25U1!U9C@4^N<CNG\1?:;">W>!%Y#CJ,'H:TA#FU>RW,:M50M%;O8T-0URUT
M^.%VS*)ONE.1BFW.O6UM=00,DA,P!! Z9J"$:/;*NDR2)-- #)L<9/J?_P!5
M0VFO:/J4,E]-$(A:L%WRKT],4>TH)V?F6L-C9Q<DK;=._P"=^ANBY@:<PB5#
M*!DIGFI:P/L-K'-)KMK(\^5+JJG@DU>T;4I-3M6EDA\HJV/8TY07+SPU1G&K
M)3]G45GK]QHT45P.M^.K_3/'MOH,5O UO(4#.V=WS#ZUFDWL;-I'?45P?C+X
M@2:+J4.DZ1!'=Z@Y =6R0N>@X[UV6FO>2:= ^H)&ETR R+'G:#Z"AII7!--V
M+5%(2 "2< =37(>'/'$.N^)M2TH*BK ?W##K(!P:$FP;2.PHHKE?&^OZOH-G
M;2:1I_VR220JX\MFVC'M0E=V!NR.JHKQ>7XL>)X+E+:;2;:*9\;4>-U)STX)
MKV"P>XDL+=[M%2X:,&15Z!L<BG*+CN)23V+%%<%XY\<7_AC6+&SM;>"1)URQ
MD!SUQQ@UWBG*@^HI--*XTTW86BD9@BEF("@9)-<CX1\<0^)]4U2S553[/)F
MCK)'TS^?\Z+-ZA='7T444AF9K:7[V2BP?;)O&<'!Q[5#?2ZG9Z )+>%9;X!=
MP _,^]-U^QFNC!)'=B!(S\V3C\:K^)[*6YM;6X34Q:10-EW)P#G'-76=J*M_
MP?O%@XJ6,]_1:;ZI_):^1-IVF0,\6M7UN(;]H_WG/ .,9Q]*G:TT?5K.6SC$
M31LVYQ'P<^M.U*(ZIH3+9RA_,4%6!X:L/PSH]]:ZB9YT:)%4@@_Q55.A3=)R
M;U_,C$8W$1Q,8Q3M\]/^&+UFVHV>N+IL5HJZ5&F%?\/7US5B6+5!KJ-$X6RX
M^7.![\>M5-8@&HZ_9Q6^J+#+!\SP \GO5C5[&2\U&V$5\(F0<QYY/O48723B
M]OO-LR5X0FM]-%IUZWWN;M>%_$1[J+XFK)8KNNE2,Q#&?FVU[F!A0,YP*\L\
M2^'=6N_BC::C!8RR6:M$6E ^48'-53=F935T9GPK2QO/$=[<ZF[/K"DF-9?U
M(]Z]GKRKQMX+U&UU^#7_  U"YG+[I(XNH;U^AKT71;NZOM)@GOK5[6Y*XDB?
MJ#2GKJ@AIH8GQ#U\:#X6G:-L7%P/*B]>>I_*O';.VO/",VB^(?-5A.VYE#<J
M,]#]17<>-/#^N>+_ !C;V@M9H=+A^03D?+[M45_\'"MA*UOJLTTJ*3'&Z\$^
ME7%Q2LR))MZ'JEI=17MG#=0L&CE0.I'H:2]NX;"RFNYV"Q0H78GT%<C\-DUB
MST)M.U>SF@:W;]TT@^\I[?A4/Q.CUN_TF+3-(LIITF.9WC'0#M^-9\OO6-+^
M[<Y/P9:S>-/'MSK]XI-M;/O0'IG^$?UKV>O#M!3X@>';'['I^D.D1?<=T())
M^M>TV#SOI]L]TNVX:)3*N.C8Y_6JJ;BAL>1?%[_D9])_W!_Z%7L:?ZM?H*\O
M^)GA[5M7\0:;/86,L\4:X=D' ^:O45&$4'L*4OA01^)G%?$[Q!_8OA>2WB?%
MU>YA3!Y"_P 1_+C\:\NTZ*[\":QH6L/(KQ74>^54(.%)^93[[2#76^)_#.M^
M,_'8CFMIK;2X1Y:3L.,#DD?4_P!*CU7X/21Z9-+:ZG-<W$2%HHG7AB.U:1<4
MK,B2DW='K<4J30I+&P:-U#*PZ$'H:*Y;X>?VM%X8CLM7M)8)[5O+0R#[Z=1^
M73\J*Q:L[&J=T;NK:8NJV@@:1H\-N!%9L(TO6K%]&+.Z1*.>A..XKH:R;W3F
MMK6>32H5CNI#R1UQ[9K2+4X^SE\NWS,9*5*HJ]/=;]]-K%&UFO\ 3M8&FQ6)
M&E0Q$K)C)X&<Y]<]JC'B6[U'2;N;3;%_M$+A0KC.0>]6)=7N](TVT^W0F6XD
M)#8.,#/\ZDN=:BL+NV@CLSMG 8D#&,^WK6?U6KM%Z:_TCI_M+#_%4A[RY>_X
M^;ZD5GI\";->OX#%?"/,@!X!Z9QZT6=M9ZSJ/]JPRR H0&C([@5*L.JR:W()
ML-I[9&TXP1V_&M6UM+>SC\NWB$:DY(%:14:,;1>K[?C?S.:K.>+J)S7NKH_+
M:WD3U ]W''<K P?>PW#"G&/K4]0O;*]PLQ8AE0KCZUFK=365^A&-0MF4,),@
MH7X'84UM2@6%)6WA7.%^0Y-1QZ/;Q+A,J3&8R0.N>]!TF)[:."1RRQYQ@8J[
M4S.]6VR+0NH6,0#C,HRGO47]I6V^5=YS$"6^4]NN*C;2XWECD,L@>, )C@#%
M._LR#RYU'WIB=SXYYHM +U>R)5O865#EAO!*Y7&<#-(+Z$R1H-Y+KO4[3C%0
MG31Y$48F96CSM95 X/!&*F6SC5HR"?W<9C ]J7N#3J"'4+<"/!9BXR JDG'K
M4D=U'+.\*$ED^]QQ5<::(S&T,SQNB["P .X9S4JV86^-UYC9*XV@8'X^M#4.
M@)U.I9HHHJ#4**** "BBB@!,T9HHH :\<<H D17 .0&&:&CC9E9D4LOW21R*
M**+BLAV:,T44##-&:** #-&:** #-&:** #-&:** #-&:** #-&:** #-&:*
(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
